Gosset Egalet General Information
Egalet was a specialty pharmaceutical company focused on developing innovative treatments for pain using its proprietary Guardian Technology™, which provided physical and chemical barriers against misuse or abuse—primarily targeting the U.S. prescription opioid market. Its commercialized products included ARYMO ER (morphine sulfate extended-release), OXAYDO (oxycodone HCl), and SPRIX Nasal Spray (ketorolac tromethamine). The company's lead pipeline candidates were also based on this technology platform aimed at deterring abuse while providing effective analgesia for patients with moderate-to-severe or chronic pain conditions. After operating independently through the mid-to-late 2010s—including an IPO under the symbol EGLT—the company was rebranded as Zyla Life Sciences before being acquired by Assertio Therapeutics around late 2019–2020[1][3][5][6].
Contact Information
USA
Drug Pipeline
Key Partnerships
Acura Pharmaceuticals
Egalet Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Apr 8, 2015 | $60.0M | Completed | Commercial |